Dergiler / İstanbul Kuzey Klinikleri / 2022 / Cilt: 9 - Sayı: 3

Evaluation of neuropathic pain with diverse pathophysiologies in childhood cancers

Sayfa
241–247
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Opioid administration was more common as the disease stage progressed (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: Neuropathic pain (NP) is caused by damage or disease affecting the somatosensory nervous system.
📊
Temel Bulgular & Veri:METHODS: Patients with cancer having NP between 5 and 18 years of age who were followed up in the pediatric oncology clinic of Okmeydani Training and Research Hospital between January 2015 and April 2019 were included in this study.
💡
Sonuç & Katkı:Opioid administration was more common as the disease stage progressed (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: Neuropathic pain (NP) is caused by damage or disease affecting the somatosensory nervous system. The aim of this study was to evaluate the clinical characteristics, pathophysiologies, and treatments applied in pediatric cancer patients with NP. METHODS: Patients with cancer having NP between 5 and 18 years of age who were followed up in the pediatric oncology clinic of Okmeydani Training and Research Hospital between January 2015 and April 2019 were included in this study. NP was described as tingling, burning, and stinging. Patients with acute lymphoblastic leukemia and brain tumors were excluded from the study. A number of pediatric cancer patients were also recorded. Patients’ age, gender, cancer diagnosis, NP characteristics and causes, treatments, and response to those treatments were investigated retrospectively and groups of NP according to their pathophysiological mechanism were established. RESULTS: NP was found in 26 (16%) of 160 patients followed up for childhood cancers. The average age was 11.8±4 years. Ten of the patients (38.4%) were female, and 16 (61.5%) were male. Osteosarcoma was the most common diagnosis in 10 (38%) patients. The most common cause of NP was compression of a nerve/root/spinal cord in 9 (35%) patients and the second most common was related with limb-sparing surgery. NP was found to be associated with chemotherapy (CT) in 5 (19%) patients, mostly with vincristine. Gabapentin was administered in a total of 22 (85%) patients for treatment. Opioid administration was more common as the disease stage progressed (p

🔖

Bu Makaleye Atıf Yap

UZUNHAN, T. A., SEN, H. S. (2022). Evaluation of neuropathic pain with diverse pathophysiologies in childhood cancers. İstanbul Kuzey Klinikleri, Cilt: 9 - Sayı: 3, 241–247. https://ajindex.com/articles/551227

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:1147–53
  2. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for1. Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:1147–53.clinical and research purposes. Neurology 2008;70:1630–5
  3. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3–14
  4. Howard RF, Wiener S, Walker SM. Neuropathic pain in children. Arch Dis Child 2014;99:84–9
  5. Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep 2006;10:275– 8
  6. Anghelescu DL, Steen BD, Wu H, Wu J, Daw NC, Rao BN, et al. Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatr Blood Cancer 2017;64
  7. Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012;54:347–52
  8. Anghelescu DL, Faughnan LG, Popenhagen MP, Oakes LL, Pei D, Burgoyne LL. Neuropathic pain referrals to a multidisciplinary pediatric cancer pain service. Pain Manag Nurs 2014;15:126–31
  9. Krumova EK, Geber C, Westermann A, Maier C. Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep 2012;12:393–402
  10. Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 2013;21:847–56
  11. Anghelescu DL, Tesney JM. Neuropathic pain in pediatric oncology: A clinical decision algorithm. Paediatr Drugs 2019;21:59–70
  12. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006;367:1618–25
  13. Foell J, Bekrater-Bodmann R, Diers M, Flor H. Mirror therapy for phantom limb pain: brain changes and the role of body representation. Eur J Pain 2014;18:729–39
  14. Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, et al. Efficacy